Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor

被引：26

作者：

Maekawa, R ^{[1
]}

Maki, H ^{[1
]}

Wada, T ^{[1
]}

Yoshida, H ^{[1
]}

Nishida-Nishimoto, K ^{[1
]}

Okamoto, H ^{[1
]}

Matsumoto, Y ^{[1
]}

Tsuzuki, H ^{[1
]}

Yoshioka, T ^{[1
]}

机构：

[1] Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan

来源：

CLINICAL & EXPERIMENTAL METASTASIS | 2000年 / 18卷 / 01期

关键词：

MMP; MMP inhibitor; anti-metastatic efficacy; safety;

D O I：

10.1023/A:1026553414492

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The anti-metastatic efficacy and safety of a newly-developed matrix metalloproteinase (MMP) inhibitor were examined. MMI-166, a N-sulfonylamino acid derivative, inhibited the enzyme activity of MMP-2, 9, and 14 but not MMP-1, 3 or 7. Daily oral administration of MMI-166 resulted in potent inhibition of metastatic lung colonization of Lewis lung carcinoma injected via the tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen at inhibition levels of 43% and 63%, respectively. Daily administration of MMI-166 also resulted in prolonged survival of mice given intraperitoneal implantation of Ma44 human lung cancer cells. The anti-metastatic activity of MMI-166 was as effective as that of other MMP inhibitors with broad inhibitory spectrum. MMI-166 did not affect in vitro tumor cell growth. Neither body weight losses nor hematotoxicity was observed during long-term treatment, indicating the safety of MMI-166 in mice. These results indicate that the selective MMP inhibitor MMI-166 has therapeutic potential as an anti-metastasis agent.

引用

页码：61 / 66

页数：6

共 45 条

[1]

ALLEY MC, 1988, CANCER RES, V48, P589

[2]

[Anonymous], 2003, Drugs R&D, V4, P198, Patent No. 9402447

[3] Recent advances in matrix metalloproteinase inhibitor research [J].

Beckett, RP ;

Davidson, AH ;

Drummond, AH ;

Huxley, P ;

Whittaker, M .

DRUG DISCOVERY TODAY, 1996, 1 (01) :16-26

[4] DIRECT EVIDENCE LINKING EXPRESSION OF MATRIX METALLOPROTEINASE-9 (92-KDA GELATINASE/COLLAGENASE) TO THE METASTATIC PHENOTYPE IN TRANSFORMED RAT EMBRYO CELLS [J].

BERNHARD, EJ ;

GRUBER, SB ;

MUSCHEL, RJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4293-4297

[5] GROWTH OF MOUSE BONE MARROW CELLS IN VITRO [J].

BRADLEY, TR ;

METCALF, D .

AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1966, 44 :287-&

[6] ASSOCIATION BETWEEN EXPRESSION OF ACTIVATED 72-KILODALTON GELATINASE AND TUMOR SPREAD IN NON-SMALL-CELL LUNG-CARCINOMA [J].

BROWN, PD ;

BLOXIDGE, RE ;

STUART, NSA ;

GATTER, KC ;

CARMICHAEL, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (07) :574-578

[7]

BROWN PD, 1993, CURR OPIN INVEST DR, V2, P617

[8] INHIBITION OF THE METASTATIC SPREAD AND GROWTH OF B16-BL6 MURINE MELANOMA BY A SYNTHETIC MATRIX METALLOPROTEINASE INHIBITOR [J].

CHIRIVI, RGS ;

GAROFALO, A ;

CRIMMIN, MJ ;

BAWDEN, LJ ;

STOPPACCIARO, A ;

BROWN, PD ;

GIAVAZZI, R .

INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (03) :460-464

[9] Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis [J].

Conway, JG ;

Trexler, SJ ;

Wakefield, JA ;

Marron, BE ;

Emerson, DL ;

Bickett, DM ;

Deaton, DN ;

Garrison, D ;

Elder, M ;

McElroy, A ;

Willmott, N ;

Dockerty, AJP ;

McGeehan, GM .

CLINICAL & EXPERIMENTAL METASTASIS, 1996, 14 (02) :115-124

[10]

CORCORAN ML, 1995, ADV EXP MED BIOL, V385, P151

← 1 2 3 4 5 →